Victoria Lock

434 total citations
11 papers, 353 citations indexed

About

Victoria Lock is a scholar working on Oncology, Cell Biology and Genetics. According to data from OpenAlex, Victoria Lock has authored 11 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Cell Biology and 4 papers in Genetics. Recurrent topics in Victoria Lock's work include Cancer-related Molecular Pathways (6 papers), Advanced Breast Cancer Therapies (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Victoria Lock is often cited by papers focused on Cancer-related Molecular Pathways (6 papers), Advanced Breast Cancer Therapies (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Victoria Lock collaborates with scholars based in United Kingdom and United States. Victoria Lock's co-authors include John F. Lyons, Matthew Squires, Daruka Mahadevan, Hilary Calvert, Ruth Plummer, Neil T. Thompson, Murray Yule, Sandra Kurtin, Tomislav Dragovich and Hendrik‐Tobias Arkenau and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Victoria Lock

11 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Victoria Lock United Kingdom 9 207 187 126 73 43 11 353
Keyu Gao China 7 239 1.2× 136 0.7× 155 1.2× 64 0.9× 18 0.4× 11 385
Ernest Medina United States 6 444 2.1× 160 0.9× 101 0.8× 46 0.6× 45 1.0× 9 607
Rachel E. Gershman United States 3 190 0.9× 171 0.9× 221 1.8× 24 0.3× 35 0.8× 3 332
Adelaida Piera Spain 5 229 1.1× 107 0.6× 94 0.7× 31 0.4× 16 0.4× 7 336
Nandini Sakurikar United States 8 236 1.1× 136 0.7× 100 0.8× 19 0.3× 29 0.7× 10 337
Matthias Reule United Kingdom 6 167 0.8× 103 0.6× 69 0.5× 20 0.3× 22 0.5× 11 273
Fanmao Zhang United States 6 270 1.3× 181 1.0× 148 1.2× 28 0.4× 22 0.5× 8 421
Neele Drobnitzky United Kingdom 6 421 2.0× 168 0.9× 56 0.4× 49 0.7× 26 0.6× 6 497
Elizabeth Moskatel United States 3 318 1.5× 96 0.5× 27 0.2× 57 0.8× 35 0.8× 4 389
Luana D’Artista Italy 7 414 2.0× 228 1.2× 76 0.6× 25 0.3× 32 0.7× 9 496

Countries citing papers authored by Victoria Lock

Since Specialization
Citations

This map shows the geographic impact of Victoria Lock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Lock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Lock more than expected).

Fields of papers citing papers by Victoria Lock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Lock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Lock. The network helps show where Victoria Lock may publish in the future.

Co-authorship network of co-authors of Victoria Lock

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Lock. A scholar is included among the top collaborators of Victoria Lock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Lock. Victoria Lock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Moreno, Lucas, Lynley V. Marshall, Andrew D.J. Pearson, et al.. (2014). A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. Clinical Cancer Research. 21(2). 267–273. 39 indexed citations
2.
Foran, James M., Farhad Ravandi, William G. Wierda, et al.. (2013). A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia. 14(3). 223–230. 37 indexed citations
3.
Mahadevan, Daruka, Sandra Kurtin, James M. Cleary, et al.. (2012). First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3028–3028. 17 indexed citations
4.
Arkenau, Hendrik‐Tobias, Ruth Plummer, L. Rhoda Molife, et al.. (2011). A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Annals of Oncology. 23(5). 1307–1313. 52 indexed citations
5.
Mahadevan, Daruka, Ruth Plummer, Matthew Squires, et al.. (2011). A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology. 22(9). 2137–2143. 73 indexed citations
6.
Shapiro, Geoffrey I., B. J. Dezube, Donald P. Lawrence, et al.. (2010). Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3069–3069. 9 indexed citations
7.
Squires, Matthew, Laurence Cooke, Victoria Lock, et al.. (2010). AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples. Molecular Cancer Therapeutics. 9(4). 920–928. 49 indexed citations
8.
Yap, Timothy A., Simon P. Heaton, Mike I. Walton, et al.. (2010). AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth. Molecular Cancer Therapeutics. 9(5). 1100–1110. 50 indexed citations
9.
Kristeleit, Rebecca, Hilary Calvert, Hendrik‐Tobias Arkenau, et al.. (2009). A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2566–2566. 19 indexed citations
10.
Mahadevan, Daruka, Ruth Plummer, M. Squires, et al.. (2008). A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3533–3533. 6 indexed citations
11.
Squires, Matthew, Ruth E. Feltell, Victoria Lock, et al.. (2007). AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.. Blood. 110(11). 3127–3127. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keyu Gao Breakdown of academic impact, for papers by Ernest Medina Breakdown of academic impact, for papers by Rachel E. Gershman Breakdown of academic impact, for papers by Adelaida Piera Breakdown of academic impact, for papers by Nandini Sakurikar Breakdown of academic impact, for papers by Matthias Reule Breakdown of academic impact, for papers by Fanmao Zhang Breakdown of academic impact, for papers by Neele Drobnitzky Breakdown of academic impact, for papers by Elizabeth Moskatel Breakdown of academic impact, for papers by Luana D’Artista
Rankless by CCL
2026